



NEWS RELEASE

Onco-Innovations Appoints Dr. Dennis Hall to Scientific & Clinical Advisory Board

Vancouver, Canada – July 20, 2025 – Onco-Innovations Limited (CBOE CA: **ONCO**) (Frankfurt: **W1H**, WKN: **A3EKSZ**) ("**Onco**" or the "**Company**") is pleased to announce the appointment of Dr. Dennis Hall, Professor of Chemistry at the University of Alberta, to its Scientific and Clinical Advisory Board.

Dr. Hall is internationally recognized for his pioneering work in organoboron chemistry, catalysis, and medicinal chemistry, including the development of DNA repair inhibitors. He currently holds the Tier 1 Canada Research Chair in Boron Chemistry for Catalysis and Drug Discovery, and leads a multidisciplinary research team dedicated to the development of novel synthetic and biological applications of boron-containing compounds.¹

With over 175 peer-reviewed publications, two books, and 15 book chapters, Dr. Hall's contributions span catalysis, heterocyclic chemistry, and medicinal chemistry. He has mentored more than 75 graduate students and postdoctoral fellows, and his work has been widely cited with over 18,000 citations and an h-index of 70.² Among his numerous accolades are the Arthur C. Cope Scholar Award (2024) from the American Chemical Society³, the R. U. Lemieux Award (2021) from the Canadian Society for Chemistry⁴, and a Killam Research Fellowship (2019–2021). He was elected a Fellow of the Royal Society of Canada in 2017.⁵

As part of his role, Dr. Hall will serve on the Scientific and Clinical Advisory Board and provide strategic advice to the Company on its Research and Development agenda, including clinical discovery, synthesis and manufacturing, pre-clinical testing, and clinical translation plans associated with Polynucleotide Kinase 3 Phosphatase (PNKP) Inhibitor Technology NP/A83. He will also collaborate with the Company's scientific and clinical leadership, as well as external partners, to advance oncology-focused innovations.

"Dr. Hall's appointment marks a significant step in bridging advanced synthetic chemistry with translational oncology. His expertise in boron-based drug discovery is uniquely aligned with our mission to develop precision therapies, and we look forward to leveraging his insight as we push our PNKP Inhibitor Technology toward the clinic," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets

¹ <https://www.chairs-chaire.gc.ca/chairholders-titulaires/profile-eng.aspx?profileId=3535#:~:text=Research%20summary,be%20developed%20into%20drug%20candidates.>

² https://scholar.google.ca/citations?user=1Q3S-_0AAAAJ&hl=en

³ <https://cen.acs.org/acs-news/2024-Cope-Cope-Scholar-Award/102/i2>

⁴ <https://www.cheminst.ca/awards/csc/lemieux/>

⁵ <https://www.ualberta.ca/en/science/news/2019/april/dennis-hall-killam.html#:~:text=His%20perseverance%20has%20paid%20off,driving%20drug%20discovery's%20future%20focus.&text=%22Too%20many%20reaction%20steps%20in,successfully%20tackle%20this%20complex%20problem.>

solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

“Thomas O’Shaughnessy”

Chief Executive Officer

For more information, please contact:

Thomas O’Shaughnessy

Chief Executive Officer

Tel: + 1 888 261 8055

investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company’s technologies, the prospects of the Company, and the Company’s business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “potential”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to further develop, prove out or commercialize its technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.